Clinical trial Recruiting at 7 sites Observational Ages 18 to 80

Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease

Official title: Impact of Drug-Coated Balloon Procedural Factors on Angiographic and Clinical Outcomes of Percutaneous Coronary Intervention for De Novo Lesions: A Multicenter, Prospective, Observational Registry

Run by Nanjing First Hospital, Nanjing Medical University · NCT07764094 · Data updated 2026-11-12

This registry tests whether delivery time and inflation duration of drug-coated balloons affect outcomes in adults undergoing PCI for new coronary lesions.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment500 (estimated)
SponsorNanjing First Hospital, Nanjing Medical University
Academic / other
Locations7 sites (Chuzhou, Anhui and 6 other locations)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedDecember 31, 2027
Study endsJune 30, 2028
Registry record updatedAugust 28, 2026
Trial IDNCT07764094 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 and older with stable CAD or unstable angina undergoing PCI for de novo lesions suitable for a DCB strategy.

Probably not a fit

Patients with recent MI, severe comorbidity, or contraindications to DCB components or dual antiplatelet therapy may not derive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry analyzes how specific drug-coated balloon procedural factors, such as Y-to-B delivery time and inflation duration, influence both angiographic results and clinical outcomes in patients with de novo coronary lesions undergoing PCI. The study collects data on procedural details and subsequent outcomes to identify potential optimization strategies for the DCB treatment process. Based on the findings, new techniques and pretreatment approaches may be proposed to improve effectiveness and safety of DCB use. The design focuses on real-world practice across several hospitals in Anhui and Jiangsu, with adults meeting defined eligibility criteria. Outcome assessment will emphasize both short-term and longer-term clinical and imaging endpoints.

Why it matters

Potential benefit: If successful, the study could guide clinicians in optimizing DCB procedures to improve vessel healing and reduce adverse events.

How similar studies have gone: Prior work suggests procedural variables can influence DCB outcomes, though this registry may provide more precise guidance for optimized techniques.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years
2. Stable coronary artery disease or unstable angina
3. De novo coronary lesion (reference vessel diameter 2.25-4.0 mm; lesion length ≤40 mm)
4. Planned DCB strategy for PCI
5. Written informed consent

Exclusion Criteria:

1. Acute myocardial infarction within 72 hours
2. Severe heart failure (NYHA class IV)
3. Severe hepatic or renal insufficiency
4. Allergy to drug-coated balloon components or antiplatelet agents, or intolerance to dual antiplatelet therapy
5. Life expectancy \<12 months
6. Pregnancy or breastfeeding
7. Concurrent participation in another clinical trial
8. In-stent restenosis
9. Unsuccessful recanalization of main vessel or side branch chronic total occlusion
10. Hemodynamic instability

Where it's running

  • Chuzhou First People's Hospital
    Chuzhou, Anhui, China
    Recruiting
  • Tongling People's Hospital
    Tongling, Anhui, China
    Recruiting
  • Huai'an Second People's Hospital
    Huai'an, Jiangsu, China
    Recruiting
  • Lianyungang First People's Hospital
    Lianyungang, Jiangsu, China
    Recruiting
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
    Recruiting
  • Xuzhou Second People's Hospital
    Xuzhou, Jiangsu, China
    Recruiting
Show 1 more location
  • Yixing People's Hospital
    Yixing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.